BIOANALYTICAL SYSTEMS, INC.
NOTV US45783Q1004
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
256% | -88% | -27% | 6% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Neff R Matthew O |
1.43 USD |
2,000 Sold |
2,858 USD |
01/10/2025 | 01/10/2025 |
Neff R Matthew O |
1.67 USD |
2,000 Sold |
3,338 USD |
02/09/2025 | 02/09/2025 |
Neff R Matthew |
1.91 USD |
2,000 Sold |
3,818 USD |
01/08/2025 | 01/08/2025 |
Neff R Matthew |
1.81 USD |
2,000 Sold |
3,621 USD |
01/07/2025 | 01/07/2025 |
Neff R Matthew |
1.81 USD |
2,000 Sold |
3,621 USD |
01/07/2025 | 01/07/2025 |
Neff R Matthew |
2.62 USD |
2,000 Sold |
5,246 USD |
02/06/2025 | 02/06/2025 |
Neff R Matthew |
2.62 USD |
2,000 Sold |
5,246 USD |
02/06/2025 | 02/06/2025 |
Coelho Mary Theresa |
2.35 USD |
5,500 Sold |
12,916 USD |
01/04/2025 | 01/04/2025 |
Taylor Beth CFO |
4.01 USD |
4,370 Sold |
17,507 USD |
18/02/2025 | 18/02/2025 |
Freeman Jeffrey Brennan VP |
4.05 USD |
1,339 Sold |
5,416 USD |
18/02/2025 | 18/02/2025 |